SCL:NYSEStepan Company Analysis
Data as of 2026-04-30 - not real-time
$48.93
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The stock is trading below its twenty‑day, fifty‑day and two‑hundred‑day moving averages, with a bearish MACD histogram and an RSI hovering around the neutral zone. Volume has been trending upward, providing some support to the price, which sits just above the identified support level and well below the resistance zone.
Fundamental picture: Forward earnings estimates are positive, delivering a modest forward price‑to‑earnings multiple that suggests the shares are undervalued relative to earnings expectations. The market price is below book value, and the dividend yield remains attractive, yet profitability is negative, free cash flow is flat and debt levels are high, raising questions about cash‑flow sustainability.
Recent developments: Q1 results showed an adjusted earnings‑per‑share beat, offset by a revenue shortfall and a net loss driven by restructuring charges. The board reaffirmed the quarterly dividend, maintaining the current payout ratio despite the cash‑flow constraints.
Fundamental picture: Forward earnings estimates are positive, delivering a modest forward price‑to‑earnings multiple that suggests the shares are undervalued relative to earnings expectations. The market price is below book value, and the dividend yield remains attractive, yet profitability is negative, free cash flow is flat and debt levels are high, raising questions about cash‑flow sustainability.
Recent developments: Q1 results showed an adjusted earnings‑per‑share beat, offset by a revenue shortfall and a net loss driven by restructuring charges. The board reaffirmed the quarterly dividend, maintaining the current payout ratio despite the cash‑flow constraints.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support
- bearish MACD signal
- increasing volume indicating potential bounce
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- forward earnings upside and modest forward PE
- price below book value
- high dividend yield supporting total return
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- structural demand for specialty chemicals
- potential for debt reduction through cash‑flow improvements
- stable dividend income for income‑focused investors
Key Metrics & Analysis
Financial Health
Revenue Growth1.90%
Profit Margin-0.61%
P/E Ratio11.8
ROE-1.19%
ROA1.50%
Debt/Equity54.63
P/B Ratio0.9
Technical Analysis
TrendBullish
RSI40.8
Support$48.33
Resistance$52.74
MA 20$50.99
MA 50$50.69
MA 200$50.04
MACDBearish
VolumeIncreasing
Fear & Greed Index87.84
Valuation
Target Price$75.00
Upside/Downside53.28%
GradeUndervalued
TypeValue
Dividend Yield3.23%
Risk Assessment
Beta1.05
Volatility35.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.